| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,**
,**,**,**,**
,**,**
* UPRES-EA 3806, Centre Hospitalier de l’Université de Poitiers, Poitiers, France;
Institut National de la Santé et de la Recherche Médicale, Unité Mixte 564, Angers, France;
BIOalternatives, Gençay, France;
Service de Dermatologie, Centre Hospitalier de l’Université La Milétrie, Poitiers, France;
¶ Service de Chirurgie Plastique, Centre Hospitalier de l’Université La Milétrie, Poitiers, France;
|| Unité Mixte Institut National de la Santé et de la Recherche Médicale 454, Hôpital Arnaud de Villeneuve, Montpellier, France; and
# Laboratoire de Dermatologie Moléculaire, Institut Universitaire de Recherche Clinique, Montpellier, France;
** Université d’Angers, Angers, France
Cutaneous inflammatory diseases such as psoriasis vulgaris and atopic dermatitis are associated with altered keratinocyte function, as well as with a particular cytokine production profile of skin-infiltrating T lymphocytes. In this study we show that normal human epidermal keratinocytes express a functional type II oncostatin-M (OSM) receptor (OSMR) consisting of the gp130 and OSMR
components, but not the type I OSMR. The type II OSMR is expressed in skin lesions from both psoriatic patients and those with atopic dermatitis. Its ligand, OSM, induces via the recruitment of the STAT3 and MAP kinase pathways a gene expression profile in primary keratinocytes and in a reconstituted epidermis that is characteristic of proinflammatory and innate immune responses. Moreover, OSM is a potent stimulator of keratinocyte migration in vitro and increases the thickness of a reconstituted epidermis. OSM transcripts are enhanced in both psoriatic and atopic dermatitic skin as compared with healthy skin and mirror the enhanced production of OSM by T cells isolated from diseased lesions. Results from a microarray analysis comparing the gene-modulating effects of OSM with those of 33 different cytokines indicate that OSM is a potent keratinocyte activator similar to TNF-
, IL-1, IL-17, and IL-22 and that it acts in synergy with the latter cytokines in the induction of S100A7 and -defensin 2 expression, characteristic of psoriatic skin. Taken together, these results demonstrate that OSM and its receptor play an important role in cutaneous inflammatory responses in general and that the specific effects of OSM are associated with distinct inflammatory diseases depending on the cytokine environment.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This study was supported by Grant 5176 from the Association pour la Recherche contre le Cancer, by the Post-genome Program of the Région Pays de la Loire and by the Programme Hospitalier de Recherche Clinique and R&D program of the CHU de Poitiers. C.D., E.V., and K.B. were supported by Grants from the Angers Agglomeration, the Société Française d’Hématologie, Ministère de la Recherche, and the Région Poitou-Charentes, respectively.
2 K.B. and C.D. contributed equally to this work.
3 Address correspondence and reprint requests to Dr. Jean-Claude Lecron, University de Poitiers, LabCytokines, Pole Biologie Sante, 40 Avenue du Recteur Pineau, Poitiers, France. E-mail address: jean-claude.lecron{at}univ-poitiers.fr or Dr. Hugues Gascan, Institut National de la Santé et de la Recherche Médicale, Unité Mixte 564, 4 Rue Larrey, F-49933 Angers, France. E-mail address: gascan{at}univ-angers.fr
4 Abbreviations used in this paper: OSM, oncostatin M; OSMR, OSM receptor; LIF, leukemia inhibitory factor; LIFR, LIF receptor; NHEK, normal human epidermal keratinocyte; RHE, reconstituted human epidermis; CK, cytokeratin; VEGF, vascular endothelial growth factor.
This article has been cited by other articles:
|
|
 |
|
  S. G. Tangye, M. C. Cook, and D. A. Fulcher Insights into the Role of STAT3 in Human Lymphocyte Differentiation as Revealed by the Hyper-IgE Syndrome J. Immunol., January 1, 2009; 182(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Guttman-Yassky, M. A. Lowes, J. Fuentes-Duculan, L. C. Zaba, I. Cardinale, K. E. Nograles, A. Khatcherian, I. Novitskaya, J. A. Carucci, R. Bergman, et al. Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis J. Immunol., November 15, 2008; 181(10): 7420 - 7427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tjabringa, M. Bergers, D. van Rens, R. de Boer, E. Lamme, and J. Schalkwijk Development and Validation of Human Psoriatic Skin Equivalents Am. J. Pathol., September 1, 2008; 173(3): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wolf, O. M. Z. Howard, H.-F. Dong, C. Voscopoulos, K. Boeshans, J. Winston, R. Divi, M. Gunsior, P. Goldsmith, B. Ahvazi, et al. Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15 J. Immunol., July 15, 2008; 181(2): 1499 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Danilenko Review Paper: Preclinical Models of Psoriasis Vet. Pathol., July 1, 2008; 45(4): 563 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Abtin, L. Eckhart, M. Mildner, F. Gruber, J.-M. Schroder, and E. Tschachler Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to Escherichia coli FASEB J, July 1, 2008; 22(7): 2168 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Quinton, M. R. Jones, B. E. Robson, B. T. Simms, J. A. Whitsett, and J. P. Mizgerd Alveolar Epithelial STAT3, IL-6 Family Cytokines, and Host Defense during Escherichia coli Pneumonia Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Linden A Role for the Cytoplasmic Adaptor Protein Act1 in Mediating IL-17 Signaling Sci. Signal., August 7, 2007; 2007(398): re4 - re4. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
